Methods to improve induction of IgA antibodies by vaccines

Patent metadata

Field	Value
Publication number	US-10286068-B2
Application number	US-201615566884-A
Country	US
Kind code	B2
Filing date	Apr 15, 2016
Priority date	Apr 15, 2015
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an IgA response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil inhibitor in an amount effective to promote an IgA response to the vaccine antigen in the subject.

First claim

What is claimed is:

1. A vaccine composition, comprising a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an IgA response to the antigen in a subject, wherein the neutrophil inhibitor comprises sivelestat, alvelestat, elafin, or an inhibitor of phosphodiesterase type 4.

2. The vaccine composition of claim 1 formulated for intranasal administration.

3. The vaccine composition of claim 1 formulated for sublingual or oral administration.

4. The vaccine composition of claim 1 formulated for intramuscular, subcutaneous, or epicutaneous administration.

5. The vaccine composition of claim 1 formulated for intravaginal administration.

6. The vaccine composition of claim 1 , wherein the neutrophil inhibitor comprises sivelestat.

7. The vaccine composition of claim 1 , wherein the neutrophil inhibitor is an inhibitor of phosphodiesterase type 4.

8. The vaccine composition of claim 1 , wherein the vaccine antigen is a viral antigen.

9. An adjuvant composition comprising a neutrophil inhibitor and an additional adjuvant, in an amount effective to promote an IgA response to a vaccine antigen in the subject, wherein the neutrophil inhibitor comprises sivelestat, alvelestat, elafin, or an inhibitor of phosphodiesterase type 4.

10. The adjuvant composition of claim 9 formulated for sublingual or oral administration.

11. The adjuvant composition of claim 9 , wherein the additional adjuvant is an aluminium salt, TLR9 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, or squalene-based oil-in-water emulsion.

12. A method for enhancing an immune response to a vaccine antigen in a subject, comprising co-administering to the subject the vaccine antigen and a neutrophil inhibitor in an amount effective to promote an IgA response to the vaccine antigen in the subject, wherein the neutrophil inhibitor comprises sivelestat, alvelestat, elafin, or an inhibitor of phosphodiesterase type 4.

13. The method of claim 12 , wherein the adjuvant composition is administered sublingually or orally.

14. The method of claim 12 , wherein the adjuvant composition induces antigen-specific IgA in the serum and mucosal secretions.

15. The vaccine composition of claim 1 , wherein the neutrophil inhibitor comprises alvelestat.

16. The vaccine composition of claim 1 , wherein the neutrophil inhibitor comprises elafin.

17. The adjuvant composition of claim 9 , wherein the neutrophil inhibitor comprises sivelestat.

18. The adjuvant composition of claim 9 , wherein the neutrophil inhibitor comprises alvelestat.

19. The adjuvant composition of claim 9 , wherein the neutrophil inhibitor comprises elafin.

20. The adjuvant composition of claim 9 , wherein the neutrophil inhibitor is an inhibitor of phosphodiesterase type 4.

Assignees

• Ohio State Innovation Foundation

Inventors

• Boyaka Prosper

Classifications

• A61K39/0291

  Yersinia · CPC title

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61P37/04 Primary

  Immunostimulants · CPC title